Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Hills

Showing results (111-120 of 298) with videos related to

Pageof 30
Sort By:
BMJ (Clinical Research Ed.)|June 22, 2002
Evaluating drug treatments for Parkinson's disease: how good are the trials?Keith Wheatley, Rebecca L Stowe, Carl E Clarke, et al.
Annals of Neurology|May 4, 2010
Standardized discharge orders after stroke: results of the quality improvement in stroke prevention (QUISP) cluster randomized trialS Claiborne Johnston, Stephen Sidney, Nancy K Hills, et al.
Blood|April 26, 2007
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemiaAdam J Mead, David C Linch, Robert K Hills, et al.
BMC Pregnancy and Childbirth|February 27, 2010
PErineal Assessment and Repair Longitudinal Study (PEARLS): protocol for a matched pair cluster trialDebra E Bick, Christine Kettle, Sue Macdonald, et al.
Midwifery|December 29, 2005
A randomised-controlled trial in England of a postnatal midwifery intervention on breast-feeding durationLouise M Wallace, Orla M Dunn, Elizabeth M Alder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemiaSylvie D Freeman, Paul Virgo, Steve Couzens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutationsClaire L Green, Kenneth K Koo, Robert K Hills, et al.
Gut|May 14, 2013
The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatmentTom Pembroke, Adam Christian, Emma Jones, et al.
American Journal of Obstetrics and Gynecology|July 6, 2024
Betamethasone treatment-to-delivery interval, retreatment, and severe intraventricular hemorrhage in infants <28 weeks' gestationRonald I Clyman, Melissa G Rosenstein, Melissa C Liebowitz, et al.
Blood|July 24, 2010
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD statusClaire L Green, Catherine M Evans, Robert K Hills, et al.
Pageof 30

Showing results (111-120 of 298) with videos related to

Sort By:
Pageof 30
BMJ (Clinical Research Ed.)|June 22, 2002
Evaluating drug treatments for Parkinson's disease: how good are the trials?Keith Wheatley, Rebecca L Stowe, Carl E Clarke, et al.
Annals of Neurology|May 4, 2010
Standardized discharge orders after stroke: results of the quality improvement in stroke prevention (QUISP) cluster randomized trialS Claiborne Johnston, Stephen Sidney, Nancy K Hills, et al.
Blood|April 26, 2007
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemiaAdam J Mead, David C Linch, Robert K Hills, et al.
BMC Pregnancy and Childbirth|February 27, 2010
PErineal Assessment and Repair Longitudinal Study (PEARLS): protocol for a matched pair cluster trialDebra E Bick, Christine Kettle, Sue Macdonald, et al.
Midwifery|December 29, 2005
A randomised-controlled trial in England of a postnatal midwifery intervention on breast-feeding durationLouise M Wallace, Orla M Dunn, Elizabeth M Alder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemiaSylvie D Freeman, Paul Virgo, Steve Couzens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutationsClaire L Green, Kenneth K Koo, Robert K Hills, et al.
Gut|May 14, 2013
The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon α treatmentTom Pembroke, Adam Christian, Emma Jones, et al.
American Journal of Obstetrics and Gynecology|July 6, 2024
Betamethasone treatment-to-delivery interval, retreatment, and severe intraventricular hemorrhage in infants <28 weeks' gestationRonald I Clyman, Melissa G Rosenstein, Melissa C Liebowitz, et al.
Blood|July 24, 2010
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD statusClaire L Green, Catherine M Evans, Robert K Hills, et al.
Pageof 30